|Rapid Review Complete
|Recombinant Human Parathyroid Hormone
|Is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of Natpar compared with the current standard of care.
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.